Skip to main content
All lobbying filings

THE PROCTER AND GAMBLE COMPANY

Lobbying for THE PROCTER AND GAMBLE COMPANY

 Filing 2nd Quarter - Report
Reporting period
2nd Quarter 2025
Apr 1 - June 30 · Posted Jul 21, 2025
Expenses
$1,320,000.00
What this organization spent lobbying with its own staff. Reported using C: the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.
Client based in
District of Columbia

Official filing document

 Government bodies contacted 11
  • Commerce, Dept of (DOC)
  • Consumer Product Safety Commission (CPSC)
  • Executive Office of the President (EOP)
  • Food & Drug Administration (FDA)
  • Health & Human Services, Dept of (HHS)
  • HOUSE OF REPRESENTATIVES
  • Natl Economic Council (NEC)
  • Office of the Vice President of the United States
  • SENATE
  • Treasury, Dept of
  • U.S. Trade Representative (USTR)

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

 Bills named in this filing 4
  • HR 1
    An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
  • S 2003
    Strengthening Benefit Plans Act of 2025
  • HR 3749
    HER Act
  • HR 4273
    Over-the-Counter Monograph Drug User Fee Amendments
 Lobbying activity 7
Science/Technology

-H.R. 1 (One Big Beautiful Bill Act - AI Moratorium)

Manufacturing

-Issues related to U.S. Manufacturing

Taxation/Internal Revenue Code

-OECD Digital Tax Project (Global Minimum Tax Implementation) -H.R. 1 (One Big Beautiful Bill Act - Corporate/International Tax Provisions) -S.2003 (Strengthening Benefit Plans Act of 2025)

Trade (domestic/foreign)

-Issues related to IEEPA Tariffs -Issues related to the Pharmaceuticals Section 232 Trade Investigation -Issues related to Lumber Section 232 Trade Investigation

Consumer Issues/Safety/Products

-Issues related to product safety

Health Issues

-Issues related to over the counter drug policy -Issues related to ingredient labeling -H.R. 3749(IH) Health and Endocrine Research on Personal Care Products for Women Act* -H.R.4273 To amend the Federal Food, Drug, and Cosmetic Act to revise and extend the user fee program for over-the-counter monograph drugs, and for other purposes

Chemicals/Chemical Industry

-Issues related to new chemical approvals (no bill)

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem